FOL 005

Drug Profile

FOL 005

Alternative Names: FOL-005

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Follicum AB
  • Class Proteins; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hair disorders

Most Recent Events

  • 01 Mar 2017 Follicum AB completes a phase I/II trial in Hair disorders (In volunteers) in Germany (Intradermal) (NCT02793557)
  • 20 Jun 2016 Follicum AB has patent protection for FOL 005 in USA (Follicum AB website, June 2016)
  • 10 Jun 2016 Preclinical trials in Hair disorders in Germany (Intradermal) before June 2016 (Follicum website, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top